These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 25283229)

  • 1. [A case of chronic hepatitis C with pancreas divisum and acute pancreatitis during combination treatment with telaprevir/peginterferon/ribavirin].
    Morio R; Imamura M; Fukuhara T; Kan H; Fujino H; Kawaoka T; Hiramatsu A; Aikata H; Sasaki T; Chayama K
    Nihon Shokakibyo Gakkai Zasshi; 2014 Oct; 111(10):1997-2003. PubMed ID: 25283229
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Possible telaprevir-induced pancreatitis. A case study].
    Selvi Sabater P; Espuny Miró A; Muñoz Bertrán ED; Plaza Aniorte J
    Farm Hosp; 2013; 37(3):269-70. PubMed ID: 23789806
    [No Abstract]   [Full Text] [Related]  

  • 3. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection.
    Hézode C; Forestier N; Dusheiko G; Ferenci P; Pol S; Goeser T; Bronowicki JP; Bourlière M; Gharakhanian S; Bengtsson L; McNair L; George S; Kieffer T; Kwong A; Kauffman RS; Alam J; Pawlotsky JM; Zeuzem S;
    N Engl J Med; 2009 Apr; 360(18):1839-50. PubMed ID: 19403903
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in chronic hepatitis C patients.
    Zeuzem S
    J Hepatol; 2008 Aug; 49(2):157-9. PubMed ID: 18554745
    [No Abstract]   [Full Text] [Related]  

  • 5. Telaprevir for retreatment of HCV infection.
    Zeuzem S; Andreone P; Pol S; Lawitz E; Diago M; Roberts S; Focaccia R; Younossi Z; Foster GR; Horban A; Ferenci P; Nevens F; Müllhaupt B; Pockros P; Terg R; Shouval D; van Hoek B; Weiland O; Van Heeswijk R; De Meyer S; Luo D; Boogaerts G; Polo R; Picchio G; Beumont M;
    N Engl J Med; 2011 Jun; 364(25):2417-28. PubMed ID: 21696308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Simeprevir versus telaprevir with peginterferon and ribavirin in previous null or partial responders with chronic hepatitis C virus genotype 1 infection (ATTAIN): a randomised, double-blind, non-inferiority phase 3 trial.
    Reddy KR; Zeuzem S; Zoulim F; Weiland O; Horban A; Stanciu C; Villamil FG; Andreone P; George J; Dammers E; Fu M; Kurland D; Lenz O; Ouwerkerk-Mahadevan S; Verbinnen T; Scott J; Jessner W
    Lancet Infect Dis; 2015 Jan; 15(1):27-35. PubMed ID: 25482330
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Telaprevir for previously untreated chronic hepatitis C virus infection.
    Jacobson IM; McHutchison JG; Dusheiko G; Di Bisceglie AM; Reddy KR; Bzowej NH; Marcellin P; Muir AJ; Ferenci P; Flisiak R; George J; Rizzetto M; Shouval D; Sola R; Terg RA; Yoshida EM; Adda N; Bengtsson L; Sankoh AJ; Kieffer TL; George S; Kauffman RS; Zeuzem S;
    N Engl J Med; 2011 Jun; 364(25):2405-16. PubMed ID: 21696307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Telaprevir, PEG-IFNα-2b and ribavirin combination therapy for difficult to treat patients with genotype 2 chronic hepatitis C].
    Nishimura T
    Nihon Rinsho; 2015 Dec; 73 Suppl 9():193-8. PubMed ID: 26845929
    [No Abstract]   [Full Text] [Related]  

  • 9. Telaprevir for previously treated chronic HCV infection.
    McHutchison JG; Manns MP; Muir AJ; Terrault NA; Jacobson IM; Afdhal NH; Heathcote EJ; Zeuzem S; Reesink HW; Garg J; Bsharat M; George S; Kauffman RS; Adda N; Di Bisceglie AM;
    N Engl J Med; 2010 Apr; 362(14):1292-303. PubMed ID: 20375406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infections.
    Foster GR; Hézode C; Bronowicki JP; Carosi G; Weiland O; Verlinden L; van Heeswijk R; van Baelen B; Picchio G; Beumont M
    Gastroenterology; 2011 Sep; 141(3):881-889.e1. PubMed ID: 21699786
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection.
    McHutchison JG; Everson GT; Gordon SC; Jacobson IM; Sulkowski M; Kauffman R; McNair L; Alam J; Muir AJ;
    N Engl J Med; 2009 Apr; 360(18):1827-38. PubMed ID: 19403902
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa-2a or -2b to patients with chronic hepatitis C.
    Marcellin P; Forns X; Goeser T; Ferenci P; Nevens F; Carosi G; Drenth JP; Serfaty L; De Backer K; Van Heeswijk R; Luo D; Picchio G; Beumont M
    Gastroenterology; 2011 Feb; 140(2):459-468.e1; quiz e14. PubMed ID: 21034744
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Cutaneous adverse events of telaprevir/peginterferon/ribavirin therapy for chronic hepatitis C: A multicenter prospective cohort study].
    Lorcy S; Gaudy-Marqueste C; Botta D; Portal I; Quiles N; Oulies V; Mancini J; Grob JJ; Richard MA
    Ann Dermatol Venereol; 2016 May; 143(5):336-46. PubMed ID: 27161648
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The efficacy and safety of telaprevir-based regimens for treating chronic hepatitis C virus genotype 1 infection: a meta-analysis of randomized trials.
    Yang D; Liang HJ; Li D; Wei X; Ma L; Jia Z
    Intern Med; 2013; 52(6):653-60. PubMed ID: 23503406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Telaprevir twice daily is noninferior to telaprevir every 8 hours for patients with chronic hepatitis C.
    Buti M; Agarwal K; Horsmans Y; Sievert W; Janczewska E; Zeuzem S; Nyberg L; Brown RS; Hézode C; Rizzetto M; Paraná R; De Meyer S; De Masi R; Luo D; Bertelsen K; Witek J
    Gastroenterology; 2014 Mar; 146(3):744-753.e3. PubMed ID: 24316262
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pegylated interferon and ribavirin: A therapeutic option in patients who fail to respond to telaprevir-based triple therapy?
    Pascale A; Chazouillères O; Serfaty L
    Hepatology; 2013 Aug; 58(2):828. PubMed ID: 23315935
    [No Abstract]   [Full Text] [Related]  

  • 17. Peginterferon Lambda-1a/Ribavirin with Daclatasvir or Peginterferon Alfa-2a/Ribavirin with Telaprevir for Chronic Hepatitis C Genotype 1b.
    Flisiak R; Kawazoe S; Znoyko O; Assy N; Gadano A; Kao JH; Lee KS; Zwirtes R; Portsmouth S; Dong Y; Xu D; Kumada H; Srinivasan S
    J Interferon Cytokine Res; 2016 Nov; 36(11):635-643. PubMed ID: 27327078
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insulin resistance and response to telaprevir plus peginterferon α and ribavirin in treatment-naive patients infected with HCV genotype 1.
    Serfaty L; Forns X; Goeser T; Ferenci P; Nevens F; Carosi G; Drenth JP; Lonjon-Domanec I; DeMasi R; Picchio G; Beumont M; Marcellin P
    Gut; 2012 Oct; 61(10):1473-80. PubMed ID: 22387529
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost utility of telaprevir-PR (peginterferon-ribavirin) versus boceprevir-PR and versus PR alone in chronic hepatitis C in The Netherlands.
    Vellopoulou A; van Agthoven M; van der Kolk A; de Knegt RJ; Berdeaux G; Cure S; Bianic F; Lamotte M
    Appl Health Econ Health Policy; 2014 Dec; 12(6):647-59. PubMed ID: 25103219
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful treatment after short course of telaprevir-based therapy in chronic hepatitis C infected patient.
    Dutilh JC; Arends JE
    Neth J Med; 2013 Sep; 71(7):391-2. PubMed ID: 24038569
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.